Nilvanstomig

Biologic (subtype unspecified)

Also known as ZG005

Phase 3underway

Evidence outlook · registrational

Hepatocellular Carcinoma: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2031-09.

Also in development:Non-Small Cell Lung Cancer · Phase 1/2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Hepatocellular Carcinoma
NCT07813572 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2026-10-20 – 2032-09 · Hepatocellular Carcinoma
What this study did
Other / comorbidity
NCT07833839 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2026-10 – 2031-12 · Neuroendocrine Carcinomas (NEC)
What this study did
Phase 2 (3)
Hepatocellular Carcinoma
NCT06558227 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2024-10-24 – 2026-10 · Hepatocellular Carcinoma
What this study did
Other / comorbidity
NCT07099547 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2025-12-02 – 2027-12 · Biliary Tract Carcinoma
What this study did
NCT06927687 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2025-06-13 – 2027-06 · Advanced Solid Tumor
What this study did
Phase 1/2 (10)
Non-Small Cell Lung Cancer
Other / comorbidity
NCT06938880 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2025-05-20 – 2028-04 · Advanced Solid Tumor
What this study did
NCT07142837 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2025-09 – 2027-12 · Advanced Solid Tumor
What this study did
NCT07080216 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2025-09-23 – 2027-12 · Cervical Cancer
What this study did
NCT07038096 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2025-09-23 – 2027-09 · Small Cell Lung Cancer, Neuroendocrine Carcinoma
What this study did
NCT06883526 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2025-05-16 – 2027-05 · Lymphoma
What this study did
NCT06372626 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2024-05-30 – 2026-08 · Neuroendocrine Carcinoma
What this study did
NCT06233292 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2022-06-17 – 2026-07-22 · Solid Tumors
What this study did
NCT06241235 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2024-03-27 – 2026-05 · Cervical Carcinoma
What this study did
NCT06239298 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2024-05-10 – 2026-05 · Solid Tumor
What this study did
Early phase / not applicable (1)
Hepatocellular Carcinoma
NCT06233994 · Changsha Taihe Hospital
2024-01 – 2026-01 · Advanced Hepatocellular Carcinoma
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Hepatocellular Carcinoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Nilvanstomig: this drugPhase 3Biologic (subtype unspecified)PD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
CabozantinibApprovedSmall moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signal
NCT01908426: Overall Survival (OS) (Up to 45 months): Cabozantinib (XL184) 10.2 months (95% CI 9.1 to 12) | Placebo 8 months (95% CI 6.8 to 9.4)
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signal
NCT03062358: Overall Survival (OS) (Up to approximately 4 years): Pembrolizumab + BSC 14.6 Months (95% CI 12.6 to 18) | Placebo + BSC 13 Months (95% CI 10.5 to 15.1)
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT02435433: Overall Survival (OS) (From Date of Randomization to Death from Any Cause (Up to 28 Months)): Ramucirumab + Best Supportive Care (BSC) 8.51 Months (95% CI 7 to 10.58) | Placebo + BSC 7.29 Months (95% CI 5.42 to 9.07)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signalNo reviewed efficacy summary in this indication
AmezalpatPhase 3Small moleculePPARα (peroxisome proliferator-activated receptor alpha)not yet gradedNo reviewed efficacy summary in this indication
ApatinibPhase 3Small moleculeVEGFR2not yet gradedNo reviewed efficacy summary in this indication
BGB-B2033Phase 3Multispecific antibodyGPC3 (glypican-3) x 4-1BB (CD137)not yet gradedNo reviewed efficacy summary in this indication
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4not yet gradedNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
JS207Phase 3Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
NamodenosonPhase 3—Adenosine A3 receptornot yet gradedNo reviewed efficacy summary in this indication
PegargiminasePhase 3Protein / enzyme therapeuticArginine-depleting pegylated arginine deiminasenot yet gradedNo reviewed efficacy summary in this indication
PenpulimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
RYZ801Phase 1/2Radiopharmaceutical—not yet gradedNo reviewed efficacy summary in this indication
ABBV-324Phase 1Antibody–drug conjugateGlypican-3 (GPC3) / Topoisomerase Inot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
SENTI-301APhase 1Cell therapyGPC3 (CAR-NK, calibrated IL-15)not yet gradedNo reviewed efficacy summary in this indication
SHR-2524Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
AZD7003
—(overall)
Cell therapyGlypican-3 (GPC3)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Nilvanstomig to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (8)
April 2027 (2)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-04 · NCT06903377 · CT.gov ↗
What to watch
Phase 1/2LymphomaRecruiting
Est. primary completion 2027-04 · NCT06883526 · CT.gov ↗
What to watch
May 2027 (2)
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2027-05 · NCT06938880 · CT.gov ↗
What to watch
Phase 2Advanced Solid TumorActive not recruiting
Est. primary completion 2027-05 · NCT06927687 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1/2Cervical CancerRecruiting
Est. primary completion 2027-08 · NCT07080216 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1/2Small Cell Lung Cancer, Neuroendocrine CarcinomaRecruiting
Est. primary completion 2027-09 · NCT07038096 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Advanced Solid TumorNot yet recruiting
Est. primary completion 2027-10 · NCT07142837 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Biliary Tract CarcinomaRecruiting
Est. primary completion 2027-12 · NCT07099547 · CT.gov ↗
What to watch
2031 (2)
September 2031 (1)
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2031-09 · NCT07813572 · CT.gov ↗
What to watch
October 2031 (1)
Phase 3Neuroendocrine Carcinomas (NEC)Not yet recruiting
Est. primary completion 2031-10 · NCT07833839 · CT.gov ↗
What to watch

See the full readout calendar ↗